TITLE

Bile Duct Carcinoma: Trends in Treatment in the Nineties

AUTHOR(S)
Martin, Robert; Bas, Heidi; Wieman, T. Jeffery; Larson, Gerald M.; Edwards, Michael; McMasters, Kelly; Reed Jr., Donald N.; Vitale, Gary C.
PUB. DATE
August 2000
SOURCE
American Surgeon;Aug2000, Vol. 66 Issue 8, p711
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Surgical resection provides the only known chance of cure for cholangiocarcinoma, and even then the 5-year survival is only 10 to 20%, and only one-third of patients are resectable for cure at the time of diagnosis. In recent years we have had considerable experience with endoscopic stenting to palliate common bile duct cancers. This has prompted us to evaluate our results for both endoscopic and surgical treatment of cholangiocarcinoma. From January 1990 through June 1999, we reviewed our endoscopic retrograde cholangiopancreatography registry and the hospital records for patients we treated for cholangiocarcinoma. Fifty patients were identified: 45 with cholangiocarcinoma and five with gallbladder cancer (who were excluded). The surgical group consisted of 16 patients: in 14 patients, resection for cure was possible whereas two had palliative procedures. There was one mortality (6%) and the median survival was 16 months. There have been no long-term surgical survivors, but 2 patients are alive at 24 months. We treated 29 patients with advanced disease with endoscopic stents (the endoscopic group) mainly for relief of obstructive jaundice. Six of 29 patients in the endoscopic group were critically ill and died in less than 4 weeks, whereas 23 patients who were in better condition survived for a mean of 10 months (range 2--84 months). We conclude that for common duct bile cancer surgical resection remains the treatment of choice but is applicable in only 30 to 35 per cent of cases. Endoscopic stenting effectively relieves jaundice and can provide long-term palliation comparable with surgical bypass; 12 of 29 patients in our endoscopic group survived 12 months or longer, and one is alive at 84 months after initial stenting.
ACCESSION #
3457659

 

Related Articles

  • Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience. Gusani, Niraj J.; Balaa, Fady K.; Steel, Jennifer L.; Geller, David A.; Marsh, J. Wallis; Zajko, Albert B.; Carr, Brian I.; Gamblin, T. Clark // Journal of Gastrointestinal Surgery;Jan2008, Vol. 12 Issue 1, p129 

    Background: Survival for patients with unresectable cholangiocarcinoma is reported to range from only 5-8 months without treatment. Systemic chemotherapy has not been shown to significantly improve survival, but newer regimens involving gemcitabine have shown increased response...

  • Radiofrequency Ablation of Recurrent Cholangiocarcinoma. Slakey, Douglas P. // American Surgeon;Apr2002, Vol. 68 Issue 4, p395 

    Intrahepatic recurrence of cholangiocarcinoma after primary resection has traditionally been considered a contraindication to surgical management. Improvements in ablative technologies such as radiofrequency ablation (RFA) offer the surgeon additional alternatives in the management of selected...

  • Diagnosis and Surgical Treatment of Intrahepatic Hepatolithiasis Combined with Cholangiocarcinoma. Zhu, Qian; Zhou, Meng; Zhou, Qing; Shi, Hong; Zhang, Qi; Yu, Zheng // World Journal of Surgery;Aug2014, Vol. 38 Issue 8, p2097 

    Background: The aim of the present study was to describe the clinical features and to assess surgical treatment of intrahepatic hepatolithiasis combined with cholangiocarcinoma (IHCC). Methods: A total of 107 patients with histopathologically proven IHCC were included in the study and were...

  • Preoperative Sequential Portal and Hepatic Vein Embolization in Patients with Hepatobiliary Malignancy. Hwang, Shin; Ha, Tae-Yong; Ko, Gi-Young; Kwon, Dong-Il; Song, Gi-Won; Jung, Dong-Hwan; Kim, Myung-Hwan; Lee, Sung-Koo; Lee, Sung-Gyu // World Journal of Surgery;Dec2015, Vol. 39 Issue 12, p2990 

    Background: Preoperative portal vein embolization (PVE) induces shrinkage of the embolized lobe and compensatory regeneration in the non-embolized lobe, but does not always induce sufficient regeneration of the future remnant liver (FRL). We previously developed preoperative sequential...

  • A six-microRNA set as prognostic indicators for bile duct cancer. Ming Wang; Tian-Fu Wen; Lin-Hai He; Chuan Li; Wen-Jiang Zhu; Murthy Trishul, Narasimha // International Journal of Clinical & Experimental Medicine;2015, Vol. 8 Issue 10, p17261 

    MicroRNAs (miRNAs) play important roles in cancer progression by altering transcriptional control. The purpose of this study is to identify and explore specific miRNAs as prognostic and predictive biomarkers for bile duct cancer (BDC) by analyzing Next-generation data. miRNA expression profiles...

  • Capsaicin Treatment Attenuates Cholangiocarcinoma Carcinogenesis. Wutka, Annika; Palagani, Vindhya; Barat, Samarpita; Chen, Xi; El Khatib, Mona; Götze, Julian; Belahmer, Hanane; Zender, Steffen; Bozko, Przemyslaw; Malek, Nisar P.; Plentz, Ruben R. // PLoS ONE;Apr2014, Vol. 9 Issue 4, p1 

    Capsaicin, the most abundant pungent molecule produced by pepper plants, represents an important ingredient in spicy foods consumed throughout the world. Studies have shown that capsaicin can relieve inflammation and has anti-proliferative effects on various human malignancies....

  • Transcatheter Arterial Chemoembolization of liver tumors: a review. Part II: Clinical applications. Moschouris, H.; Papadaki, M. G.; Matsaidonis, D. // Scientific Chronicles / Epistimonika Chronika;Oct2013, Vol. 18 Issue 4, p198 

    Transcatheter arterial chemoembolization (TACE) is the standard treatment for inoperable hepatocellular carcinoma (HCC), of intermediate stage according to BCLC (Barcelona Clinic Live Cancer) system. It is also applied in cases of hemorrhage caused by ruptured HCC, as a bridge therapy prior to...

  • Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial Stein, Alexander; Arnold, Dirk; Bridgewater, John; Goldstein, David; Jensen, Lars Henrik; Klümpen, Heinz-Josef; Lohse, Ansgar W.; Nashan, Björn; Primrose, John; Schrum, Silke; Shannon, Jenny; Vettorazzi, Eik; Wege, Henning // BMC Cancer;Jul2015, Vol. 15 Issue 1, p1 

    Background: Despite complete resection, disease-free survival (DFS) of patients with cholangiocarcinoma (CCA) is less than 65 % after one year and not more than 35 % after three years. For muscle invasive gallbladder carcinoma (GBCA), prognosis is even worse, with an overall survival (OS) of...

  • Treatment Options for Hepatobiliary and Pancreatic Cancer. Alberts, Steven R.; Gores, Gregory J.; Kirvi, George P.; Roberts, Lewis R.; Kendrick, Michael L.; Rosen, Charles B.; Chari, Suresh T.; Martenson, James A. // Mayo Clinic Proceedings;May2007, Vol. 82 Issue 5, p628 

    Hepatobillary and pancreatic cancers account for 4% of all cancers in the United States. Traditionally, these cancers have had a high mortality rate and have been poorly responsive to therapy. Because of a growing number of treatment options, patients are now living longer. For hepatocellular...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics